
Biogen, maker of the Alzheimer’s medicine Aduhelm, announced Wednesday that it would “discontinue the development and commercialization” of the controversial drug. Biogen will return the rights to Aduhelm to Neurimmune, the private firm that invented it, the company said in a statement. It’s a sobering new chapter for the drug, which first gained U.S. Food… read on > read on >